North America Circulating Tumor Cells (CTC) Liquid Biopsy Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

North America Circulating Tumor Cells (CTC) Liquid Biopsy Market Size

• The North America Circulating Tumor Cells (CTC) liquid biopsy market size was valued at USD 1.11 billion in 2025and is expected to reach USD 7.00 billion by 2033, at a CAGR of 25.9% during the forecast period
• The market growth is largely fueled by the increasing adoption of minimally invasive cancer diagnostics, coupled with rapid advancements in liquid biopsy technologies that enable early detection, real-time disease monitoring, and precision oncology across healthcare systems in the region
• Furthermore, rising cancer prevalence, strong healthcare infrastructure, and growing integration of genomics and personalized medicine approaches are significantly boosting demand for CTC-based diagnostic solutions, thereby accelerating the expansion of the industry across North America

North America Circulating Tumor Cells (CTC) Liquid Biopsy Market Analysis

• Circulating Tumor Cells (CTC) liquid biopsy technologies, enabling non-invasive detection and analysis of tumor cells circulating in the bloodstream, are increasingly essential components of modern oncology diagnostics and precision medicine approaches in both clinical and research settings due to their ability to provide real-time insights into cancer progression, metastasis, and treatment response
• The escalating demand for Circulating Tumor Cells (CTC) liquid biopsy is primarily driven by the rising incidence of cancer, growing emphasis on early and accurate diagnosis, and increasing preference for minimally invasive testing methods that improve patient outcomes while reducing reliance on traditional tissue biopsies
• The United States dominated the North America Circulating Tumor Cells (CTC) liquid biopsy market with the largest revenue share of 70.01% in 2025, characterized by advanced healthcare infrastructure, strong adoption of precision oncology, and significant R&D investments, with the country witnessing notable growth in clinical applications and cancer research programs supported by biotechnology companies and academic institutions focused on innovative single-cell and molecular detection technologies
• Canada is expected to be the fastest growing country in the North America Circulating Tumor Cells (CTC) liquid biopsy market during the forecast period due to rising government support for cancer research, increasing adoption of advanced diagnostic technologies, and expanding clinical integration of liquid biopsy solutions in oncology care pathways
• CTC Detection Methods segment dominated the North America Circulating Tumor Cells (CTC) liquid biopsy market with a market share of 43.9% in 2025, driven by continuous advancements in enrichment, isolation, and molecular characterization techniques that improve detection accuracy, sensitivity, and clinical utility in identifying rare circulating tumor cells for cancer diagnostics and monitoring

Report Scope and North America Circulating Tumor Cells (CTC) Liquid Biopsy Market Segmentation

North America Circulating Tumor Cells (CTC) Liquid Biopsy Market Trends

“Advancements in Precision Oncology Through Multi-Omics and Real-Time Cancer Monitoring”

• A significant and accelerating trend in the North America Circulating Tumor Cells (CTC) liquid biopsy market is the growing integration of CTC platforms with multi-omics technologies such as genomics, proteomics, and single-cell sequencing, significantly enhancing real-time cancer profiling and treatment personalization in oncology workflows
• For instance, CTC-based platforms such as CellSearch and Parsortix are increasingly being combined with next-generation sequencing tools to enable deeper molecular characterization of tumor cells for metastatic cancer monitoring and therapy selection
• AI and machine learning integration in CTC analysis is improving detection accuracy, enabling automated identification of rare tumor cells and predictive modeling of disease progression, while also supporting faster and more standardized clinical interpretation of complex biological data
• The seamless integration of CTC liquid biopsy systems with hospital laboratory information systems and precision oncology platforms is enabling centralized cancer monitoring, allowing clinicians to track disease evolution and treatment response through a unified digital diagnostic ecosystem
• This trend toward highly sensitive, data-driven, and integrated cancer diagnostics is reshaping clinical oncology expectations, with companies such as Menarini Silicon Biosystems and Thermo Fisher Scientific advancing automated CTC detection solutions with enhanced molecular analysis capabilities
• The demand for advanced CTC liquid biopsy technologies is growing rapidly across oncology hospitals and research centers, as healthcare providers increasingly prioritize early cancer detection, non-invasive monitoring, and personalized treatment decision-making
• Growing collaboration between biotech companies and academic research institutes is fostering innovation in CTC enrichment and analysis techniques, further expanding the clinical utility of liquid biopsy in metastatic cancer management

North America Circulating Tumor Cells (CTC) Liquid Biopsy Market Dynamics

Driver

 “Rising Cancer Burden and Growing Shift Toward Non-Invasive Cancer Diagnostics”

• The increasing prevalence of cancer across North America, coupled with the growing demand for minimally invasive diagnostic methods, is a major driver accelerating the adoption of Circulating Tumor Cells (CTC) Liquid Biopsy technologies in clinical oncology and research applications
• For instance, in April 2025, leading oncology research institutes expanded the use of CTC-based assays for real-time monitoring of metastatic breast and prostate cancer, strengthening the role of liquid biopsy in precision medicine approaches
• As healthcare providers increasingly focus on early detection and personalized treatment strategies, CTC liquid biopsy offers significant advantages through real-time tumor monitoring, enabling better treatment planning and improved patient outcomes compared to traditional tissue biopsies
• Furthermore, the rising integration of liquid biopsy into clinical trials and drug development processes is making CTC analysis a key tool for assessing therapeutic efficacy and tracking tumor evolution in cancer patients
• The growing adoption of precision oncology frameworks and increasing investment from biotechnology companies are further propelling the use of CTC liquid biopsy technologies across hospitals, diagnostic laboratories, and academic research centers
• Expanding reimbursement support for advanced cancer diagnostics in the United States is improving patient access to liquid biopsy-based testing, thereby encouraging wider clinical adoption across oncology care pathways
• Rising awareness among clinicians regarding the prognostic value of circulating tumor cells is further supporting routine incorporation of CTC analysis in cancer management protocols

Restraint/Challenge

“High Technological Complexity and Limited Clinical Standardization”

• Concerns regarding the technological complexity and lack of standardized protocols in Circulating Tumor Cells (CTC) Liquid Biopsy present a significant challenge to widespread clinical adoption, as variability in detection methods can impact result accuracy and reproducibility
• For instance, differences in CTC isolation techniques such as immunoaffinity-based capture, microfluidics, and size-based separation can lead to inconsistent clinical outcomes across laboratories and healthcare institutions
• Addressing these standardization challenges through regulatory harmonization, improved assay validation, and establishment of unified clinical guidelines is essential for increasing physician confidence and broader clinical adoption of CTC technologies
• In addition, the relatively high cost of advanced CTC detection platforms and associated molecular analysis tools can limit accessibility, particularly for smaller diagnostic centers and healthcare facilities with budget constraints
• While ongoing technological advancements are gradually improving efficiency and reducing operational costs, the perceived complexity of implementation and interpretation continues to hinder faster integration into routine clinical oncology practice
• Limited availability of skilled personnel trained in advanced liquid biopsy interpretation further constrains large-scale adoption, especially in non-specialized diagnostic laboratories
• Variability in regulatory approval pathways for novel CTC technologies across North America also slows commercialization and delays widespread clinical deployment

North America Circulating Tumor Cells (CTC) Liquid Biopsy Market Scope

The market is segmented on the basis of technology, application, and end user.

• By Technology

On the basis of technology, the North America Circulating Tumor Cells (CTC) Liquid Biopsy market is segmented into CTC detection methods, CTC enrichment methods, ex vivo positive selection, molecular (RNA)-based technologies, functional in vitro cell invasion assay, xenotransplantation models, microchips, single spiral microchannel, and negative selection & immunocytochemical technologies. The CTC detection methods segment dominated the market with the largest revenue share of 43.9% in 2025, driven by its essential role in accurately identifying and characterizing rare circulating tumor cells for cancer diagnosis and monitoring. This segment is widely adopted in oncology due to its ability to provide real-time insights into disease progression and treatment response, making it highly valuable for precision medicine. Strong integration with next-generation sequencing and single-cell analysis platforms further enhances its clinical utility. Increasing adoption across hospitals and cancer research institutes in the United States supports its dominance, while continuous improvements in immunoaffinity and microfluidic-based detection technologies are improving sensitivity and accuracy. In addition, its compatibility with multiple downstream molecular analysis techniques strengthens its position as the most widely used technology in clinical workflows.

The CTC microchips segment is expected to witness the fastest growth rate of 22.4% from 2026 to 2033, driven by rapid advancements in lab-on-a-chip and microfluidic technologies. These systems enable highly precise isolation of tumor cells with reduced sample processing time and minimal manual intervention. Increasing demand for automated and high-throughput diagnostic solutions is accelerating adoption in both research and clinical settings. Their ability to integrate multiple analytical steps on a single platform enhances efficiency and reduces operational complexity. Growing investment in miniaturized diagnostic technologies and rising focus on personalized cancer research further support segment expansion. Continuous innovation in microchip design is also improving detection sensitivity and scalability, making them increasingly attractive for future liquid biopsy applications.

• By Application

On the basis of application, the market is segmented into cancer stem cell research, multiple chromosome abnormalities, and others. The cancer stem cell research segment dominated the market with the largest revenue share of 45.6% in 2025, driven by increasing focus on understanding tumor heterogeneity and cancer recurrence mechanisms. This segment plays a critical role in studying tumor initiation, progression, and metastasis at a cellular level, making it essential for advanced oncology research. Growing emphasis on precision medicine is increasing demand for detailed cellular profiling using CTC platforms. Strong research funding and collaborations between academic institutes and biotechnology companies in North America further support its dominance. Integration with genomic and proteomic technologies enhances research accuracy, while rising use in identifying therapy-resistant cancer cells strengthens its clinical relevance. Continuous advancements in cancer biology research are further consolidating its leading position.

The multiple chromosome abnormalities segment is expected to witness the fastest growth rate of 21.9% from 2026 to 2033, driven by increasing application of CTC analysis in genetic and cytogenetic profiling. This segment enables early identification of chromosomal instability associated with cancer development and progression. Advancements in high-throughput sequencing technologies are improving the detection of complex genetic variations in tumor cells. Growing adoption of personalized treatment strategies is increasing its clinical importance in oncology decision-making. Rising use in clinical trials and cancer research studies is expanding its application scope. In addition, improved diagnostic accuracy in identifying aggressive and treatment-resistant cancers is contributing to its rapid growth.

• By End User

On the basis of end user, the market is segmented into research & academic institutes, reference laboratories, and hospitals & physician laboratories. The research & academic institutes segment dominated the market with the largest revenue share of 48.3% in 2025, driven by extensive cancer research activities and strong adoption of advanced liquid biopsy technologies. These institutes play a central role in developing and validating innovative CTC detection methods and advancing oncology research. High levels of government and private funding in North America are supporting large-scale cancer studies. Strong collaboration with biotechnology and pharmaceutical companies further accelerates technological innovation. The availability of advanced laboratory infrastructure enables complex experimental studies, while increasing focus on translational research supports the conversion of findings into clinical applications. Continuous exploration of tumor biology and metastasis mechanisms further strengthens this segment’s dominance.

The hospitals & physician laboratories segment is expected to witness the fastest growth rate of 22.6% from 2026 to 2033, driven by increasing clinical adoption of liquid biopsy for routine cancer diagnostics. Growing demand for minimally invasive and real-time cancer monitoring solutions is significantly boosting usage in hospitals. Expansion of precision oncology programs and improved reimbursement support for advanced diagnostic tests are further encouraging adoption. Integration of CTC testing into standard oncology workflows is enhancing clinical utility. Increasing physician awareness regarding the prognostic value of circulating tumor cells is also supporting growth. In addition, rising patient preference for faster, less invasive diagnostic procedures is accelerating demand across clinical settings.

North America Circulating Tumor Cells (CTC) Liquid Biopsy Market Regional Analysis

• The United States dominated the North America Circulating Tumor Cells (CTC) liquid biopsy market with the largest revenue share of 70.1% in 2025, characterized by advanced healthcare infrastructure, strong adoption of precision oncology, and significant R&D investments
• The country benefits from a highly developed healthcare infrastructure, widespread availability of advanced diagnostic laboratories, and early adoption of innovative liquid biopsy technologies for cancer detection, prognosis, and treatment monitoring
• Healthcare providers and research institutions in the U.S. highly value the non-invasive nature, high sensitivity, and real-time monitoring capability of CTC liquid biopsy solutions, particularly for managing metastatic cancers and guiding personalized therapy decisions

The U.S. Circulating Tumor Cells (CTC) Liquid Biopsy Market Insight

The U.S. Circulating Tumor Cells (CTC) Liquid Biopsy market captured the largest revenue share of 70.1% in 2025 within North America, fueled by strong adoption of precision oncology and rapid expansion of advanced cancer diagnostics. Healthcare providers are increasingly prioritizing non-invasive liquid biopsy techniques for early cancer detection, metastasis monitoring, and real-time treatment response evaluation. The growing integration of CTC testing with next-generation sequencing and single-cell analysis platforms further strengthens clinical utility. Moreover, strong R&D investments from biotechnology companies, along with extensive clinical trials and supportive regulatory frameworks, are significantly contributing to market expansion.

Canada Circulating Tumor Cells (CTC) Liquid Biopsy Market Insight

The Canada Circulating Tumor Cells (CTC) Liquid Biopsy market is expected to grow at a notable CAGR during the forecast period, driven by increasing government support for cancer research and rising adoption of advanced diagnostic technologies. The country’s strong focus on early cancer detection and precision oncology is encouraging wider use of non-invasive liquid biopsy solutions in clinical practice. Expanding collaboration between academic institutions and biotechnology companies is accelerating innovation in CTC detection platforms. In addition, growing integration of liquid biopsy into oncology treatment pathways and clinical research programs is further supporting market expansion across Canada.

Mexico Circulating Tumor Cells (CTC) Liquid Biopsy Market Insight

The Mexico Circulating Tumor Cells (CTC) Liquid Biopsy market is expected to expand at a steady CAGR during the forecast period, driven by increasing cancer incidence and gradual improvement in healthcare infrastructure. Rising awareness of early cancer diagnosis and growing adoption of advanced diagnostic tools in urban healthcare centers are supporting market growth. The expansion of private healthcare facilities and increasing availability of specialized oncology services are further contributing to adoption of liquid biopsy technologies. In addition, growing participation in regional clinical studies and improving access to modern diagnostic platforms are gradually strengthening market development in Mexico.

North America Circulating Tumor Cells (CTC) Liquid Biopsy Market Share

The North America Circulating Tumor Cells (CTC) Liquid Biopsy industry is primarily led by well-established companies, including:

• QIAGEN (Germany)
• Thermo Fisher Scientific Inc. (U.S.)
• Bio-Rad Laboratories, Inc. (U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Illumina, Inc. (U.S.)
• Sysmex Corporation (Japan)
• Menarini Silicon Biosystems S.p.A. (Italy)
• ANGLE plc (U.K.)
• Greiner Bio-One International GmbH (Austria)
• Miltenyi Biotec B.V. & Co. KG (Germany)
• RareCyte, Inc. (U.S.)
• Biolidics Limited (Singapore)
• Bio-Techne Corporation (U.S.)
• Exact Sciences Corporation (U.S.)
• Myriad Genetics, Inc. (U.S.)
• NeoGenomics Laboratories, Inc. (U.S.)
• Oncocyte Corporation (U.S.)
• Lucence Health Inc. (Singapore)
• Vortex Biosciences, Inc. (U.S.)
• Guardant Health, Inc. (U.S.)

What are the Recent Developments in North America Circulating Tumor Cells (CTC) Liquid Biopsy Market?

• In April 2025, Guardant Health expanded clinical utility of its liquid biopsy platforms in the United States by enhancing real-time cancer monitoring capabilities through advanced genomic profiling and treatment response tracking. The development strengthens the integration of circulating tumor DNA and CTC-related workflows in precision oncology, enabling improved early detection of recurrence and better clinical decision-making in cancer care
• In October 2024, U.S.-based research initiatives advanced the use of AI-powered circulating tumor cell detection systems to improve diagnostic accuracy in metastatic cancer analysis. These developments integrate machine learning algorithms with imaging platforms to enhance rare cell identification in blood samples, significantly improving sensitivity and reproducibility in liquid biopsy workflows used in oncology research and diagnostics
• In March 2023, U.S. researchers demonstrated a fully automated deep learning-based platform for circulating tumor cell detection, enabling high-throughput identification and classification of cancer cells from blood samples. The system improves scalability in clinical workflows by reducing manual analysis burden and increasing detection precision for rare tumor cells, supporting broader adoption of liquid biopsy in hospital diagnostics
• In June 2022, Menarini Silicon Biosystems strengthened its North American presence by advancing the CELLSEARCH Circulating Tumor Cell system used for metastatic cancer monitoring. The platform is widely utilized in clinical oncology for enumerating CTCs in blood samples, supporting prognosis evaluation and therapy response assessment in breast, prostate, and colorectal cancers
• In September 2021, Thermo Fisher Scientific expanded its liquid biopsy portfolio in North America by enhancing next-generation sequencing and sample preparation solutions used in circulating tumor cell and cell-free DNA analysis. These advancements support more accurate genomic profiling of cancer patients, enabling improved biomarker discovery and personalized treatment strategies in oncology research and diagnostics

SKU-66917